Literature DB >> 26920423

Intranasal administration of Exendin-4 antagonizes Aβ31-35-induced disruption of circadian rhythm and impairment of learning and memory.

Xiaohui Wang1, Li Wang2, Yunyun Xu2, Qianqian Yu2, Lin Li3, Yanlin Guo2.   

Abstract

BACKGROUND: The deposition of β-amyloid protein (Aβ) is one of the pathological characteristics of Alzheimer's disease (AD) and can disrupt circadian rhythm and impair learning and memory. Exendin-4, a therapeutic drug for type II diabetes mellitus (T2DM), exerts neuroprotective effects from the toxicity of Aβ. However, it is not clear whether Exendin-4 protects against Aβ-induced disruption of circadian rhythm. The neuroprotective effects of Exendin-4 have been studied using injection of Exendin-4 into the lateral ventricle and abdomen. However, these procedures are not suitable for clinical application.
METHODS: First, male C57BL/6 mice received triple distilled water or Exendin-4 (0.1 nmol, 0.5 nmol) by intranasal administration. Exendin-4 levels were measured in the hippocampal samples using an ELISA Kit. Then, the study examined whether intranasal or hippocampal administration of Exendin-4 antagonized Aβ-induced disruption of circadian rhythm as well as impairment of learning and memory using the wheel-running activity assay and the Morris water maze test.
RESULTS: The study showed that intranasally administered Exendin-4 passed through the blood-brain barrier. Aβ31-35 given by intrahippocampal injection disrupted circadian rhythm and impaired learning and memory in C57BL/6 mice, and Exendin-4 given by nasal cavity or hippocampal administration ameliorated Aβ31-35-induced circadian rhythm disturbance of locomotor activity and impairment of learning and memory.
CONCLUSIONS: These findings provide pivotal experimental support for further study of the neuroprotective effects and clinical application of Exendin-4.

Entities:  

Keywords:  Ameliorate; Circadian rhythm; Exendin-4; Intranasal administration; Learning and memory

Mesh:

Substances:

Year:  2016        PMID: 26920423     DOI: 10.1007/s40520-016-0548-z

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  6 in total

Review 1.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

2.  Poly-N-methylated Aβ-Peptide C-Terminal fragments (MEPTIDES) reverse the deleterious effects of amyloid-β in rats.

Authors:  Siya G Sibiya; Musa V Mbandla; Thavi Govender; Adeola Shobo; William M U Daniels
Journal:  Metab Brain Dis       Date:  2017-10-09       Impact factor: 3.584

3.  Nucleoside reverse transcriptase inhibitors (NRTIs) induce proinflammatory cytokines in the CNS via Wnt5a signaling.

Authors:  Ting Wu; Juan Zhang; Mingxing Geng; Shao-Jun Tang; Wenping Zhang; Jianhong Shu
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

4.  MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ25-35 -induced anxiety and cognitive deficits in a mouse model.

Authors:  Hei-Jen Huang; Hsin-Yu Huang; Hsiu Mei Hsieh-Li
Journal:  CNS Neurosci Ther       Date:  2018-07-05       Impact factor: 5.243

5.  D-Ser2-oxyntomodulin ameliorated Aβ31-35-induced circadian rhythm disorder in mice.

Authors:  Li Wang; Jin Zhao; Chang-Tu Wang; Xiao-Hong Hou; Na Ning; Cong Sun; Shuai Guo; Yuan Yuan; Lin Li; Christian Hölscher; Xiao-Hui Wang
Journal:  CNS Neurosci Ther       Date:  2019-08-14       Impact factor: 5.243

6.  Association between exenatide use and incidence of Alzheimer's disease.

Authors:  Bo Zhou; Julie Zissimopoulos; Hasan Nadeem; Matthew A Crane; Dana Goldman; John A Romley
Journal:  Alzheimers Dement (N Y)       Date:  2021-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.